neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: Will it play in Peoria? Part II

Journal of Clinical Oncology

Volumn 21, Issue 3, 2003, Pages 399-400

  Pritchard, Kathleen I ^a   Levine, Mark N ^a   Tu, Dongsheng ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; EDITORIAL; FEMALE; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; NOTE; OVARIECTOMY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; OVARIECTOMY; PREMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0037317628     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.038     Document Type: Editorial

References (22)

1. Osborne CK, Yochmowitz MG, Knight WA, et al: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884-2888, 1980
2. Knight WA, Osborne CK, McGuire W: Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab 9:361-368, 1980
3. Bloom ND, Tobin EH, Schreibman B, et al: The role of progesterone receptors in the management of advanced breast cancer. Cancer 45:2972-2977, 1980
4. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
5. Ferno M, Stal O, Baldetorp B, et al: Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels: South Sweden Breast Cancer Group and South-East Sweden Breast Cancer Group. Br Cancer Res Treat 59:69-76, 2000
6. Silvestrini R, Daidone MG, Benini E, et al: Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 2:2007-2013, 1996
7. Ferno M, Baldetorp B, Bendahl PO, et al: Recurrence-free survival in breast cancer improved by adjuvant tamoxifen, especially for progesterone receptor positive tumors with a high proliferation. Breast Cancer Res Treat 36:23-34, 1995
8. Bianco AR, De Laurentis M, Carlomagno C, et al: 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr)
9. Hole D, Stallard S, Holli K, et al: Hormones and breast cancer. Breast 11:188-189, 2002
10. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995
11. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
12. Yamauchi H, O'Neill A, Gelman R, et al: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15:2518-2525, 1997
13. Plunkett TA, Houston SJ, Barnes DM, et al: C-ErbB-2 is a marker of resistance to endocrine therapy in advanced breast cancer. Proc Am Soc Clin Oncol 17:103a, 1998 (abstr 397)
14. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant therapy than tamoxifen for ErbB1 and ErbB2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
15. Elledge R, Green S, Ciocca DR, et al: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 4:7-12, 1998
16. Love RR, Due NB, Havighurst T, et al: HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21:453-457, 2003
17. Lipton A, Ali S, Leitzel K, et al: Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. Proc Am Soc Clin Oncol 19:71A, 2000 (abstr 274)
18. Pritchard KI: Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: Will it play in Peoria? J Clin Oncol 19:3795-3797, 2001
19. Love RR, Due NB, Allred DC, et al: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20:2559-2566, 2002
20. Levine MN, Andrulis IL: The Her-2/neu oncogene in breast cancer: So what is new? J Clin Oncol 10:1034-1036, 1992
21. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372, 1985
22. Snapinn SM: Interpreting interaction: The classical approach. Drug Info J 32:433-438, 1998